C12N 2750/14241
Use of virus, viral particle or viral elements as a vector
C12N2750/14241 (Use of virus, viral particle or viral elements as a vector) appears on 15 US grants and 23 published applications in this corpus.
Search patents in C12N- Granted patents
- 15
- Published applications
- 23
- Assignees
- 14
- Inventors
- 44
- Latest grant
- 22 Jul 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1996 | 1 | 0 |
| 1997 | 0 | 0 |
| 1998 | 1 | 0 |
| 1999 | 1 | 0 |
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 1 | 0 |
| 2003 | 1 | 3 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 3 |
| 2007 | 1 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 2 |
| 2012 | 0 | 0 |
| 2013 | 0 | 1 |
| 2014 | 1 | 1 |
| 2015 | 0 | 0 |
| 2016 | 1 | 0 |
| 2017 | 1 | 0 |
| 2018 | 0 | 2 |
| 2019 | 0 | 0 |
| 2020 | 0 | 2 |
| 2021 | 1 | 2 |
| 2022 | 0 | 0 |
| 2023 | 0 | 0 |
| 2024 | 2 | 2 |
| 2025 | 2 | 5 |
By publication year. Applications have been published since 2001.
Subgroups
Granted patents
- C12N 2750/14243Viral genome or elements thereof as genetic vectorIndexing code13
- C12N 2750/14242Virus or viral particle as vehicleIndexing code2
- C12N 2750/14245Special targeting system for viral vectorsIndexing code2
- C12N 2750/14244Chimeric viral vector comprising heterologous viral elements for production of another viralIndexing code0
Recent patents
- Nucleic acid molecules and uses thereof for non-viral gene therapy22 Jul 2025US 12,364,774 B2Bioverativ Therapeutics Inc.
- Compositions and methods for delivering nucleic acids to cochlear and vestibular cells22 Apr 2025US 12,281,313 B2Children's Medical Center Corporation
- Nucleic acid molecules and uses thereof17 Dec 2024US 12,168,776 B2Bioverativ Therapeutics Inc.
- Methods of delivering an agent to the eye23 Apr 2024US 11,963,905 B2Massachusetts Eye and Ear Infirmary
- Methods of delivering an agent to the eye5 Jan 2021US 10,881,548 B2Massachusetts Eye and Ear Infirmary
- Erythroparvovirus compositions and methods for gene therapy16 Oct 2025US 2025/0320521 A1Synteny Therapeutics, Inc.
- Erythroparvovirus with a modified genome for gene therapy2 Oct 2025US 2025/0302994 A1Synteny Therapeutics, Inc.
- Erythroparvovirus with a modified capsid for gene therapy25 Sep 2025US 2025/0295810 A1Synteny Therapeutics, Inc.
- Nucleic acid molecules and uses thereof for non-viral gene therapy28 Aug 2025US 2025/0269067 A1Bioverativ Therapeutics Inc.
- Nucleic acid molecules and uses thereof29 May 2025US 2025/0171805 A1Bioverativ Therapeutics Inc.
Most cited
By later US patents
- Virus vectors and methods of making and administering the same197US 7,172,893 B2The University of North Carolina at Chapel Hill · 2007
- Recombinant parvovirus vectors and method of making167US 6,491,907 B1The University of North Carolina at Chapel Hill · 2002
- Optimization of expression of parvoviral rep and cap proteins in insect cells38US 8,642,314 B2Amsterdam Molecular Therapeutics (AMT) B.V. · 2014
- Optimization of expression of parvoviral rep and cap proteins in insect cells34US 9,260,724 B2uniQure IP B.V. · 2016
- B19 parvovirus capsids17US 5,508,186 AThe United States of America as represented by the Secretary of Health and Human Services · 1996